Prostate Cancer Stocks List

Prostate Cancer Stocks Recent News

Date Stock Title
May 17 SNY The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
May 17 SNY Could Novavax Become the Next Moderna?
May 16 EDAP EDAP TMS (EDAP) Q1 2024 Earnings Call Transcript
May 16 SNY Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
May 16 SNY Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
May 16 AYTU Q3 2024 Aytu Biopharma Inc Earnings Call
May 16 SNY If You'd Invested $10,000 in Novavax a Year Ago, This Is How Much You'd Have Now
May 16 EDAP EDAP TMS S.A. reports Q1 results
May 16 EDAP EDAP Reports First Quarter 2024 Financial Results
May 16 AYTU Aytu BioPharma Inc (AYTU) Q3 2024 Earnings Call Transcript Highlights: Strategic Gains Amidst ...
May 16 AYTU Aytu BioPharma, Inc. (AYTU) Q3 2024 Earnings Call Transcript
May 15 AYTU Aytu BioScience up 5% as quarterly results beat on both lines
May 15 PROF Profound Medical Annual General Meeting of Shareholders Voting Results
May 15 AYTU Aytu BioScience GAAP EPS of -$0.52 beats by $0.12, revenue of $17.99M beats by $0.64M
May 15 AYTU Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results
May 15 EDAP EDAP TMS S.A. Q1 2024 Earnings Preview
May 15 VERU Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
May 15 SNY Novavax Soars on Sanofi Deal: A Smart Buy or Post-Hype Correction?
May 15 SNY Novavax Stock Just Tripled. Is It Too Late to Buy?
May 14 AYTU Aytu BioScience Q3 Earnings Preview
Prostate Cancer

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, it can lead to difficulty urinating, blood in the urine or pain in the pelvis, back, or when urinating. A disease known as benign prostatic hyperplasia may produce similar symptoms. Other late symptoms may include feeling tired due to low levels of red blood cells.Factors that increase the risk of prostate cancer include older age, a family history of the disease, and race. About 99% of cases occur in males over the age of 50. Having a first-degree relative with the disease increases the risk two to threefold. In the United States, it is more common in the African American population than the White American population. Other factors that may be involved include a diet high in processed meat, red meat or milk products or low in certain vegetables. An association with gonorrhea has been found, but a reason for this relationship has not been identified. An increased risk is associated with the BRCA mutations. Prostate cancer is diagnosed by biopsy. Medical imaging may then be done to determine if the cancer has spread to other parts of the body.Prostate cancer screening is controversial. Prostate-specific antigen (PSA) testing increases cancer detection, but it is controversial regarding whether it improves outcomes. Informed decision making is recommended when it comes to screening among those 55 to 69 years old. Testing, if carried out, is more reasonable in those with a longer life expectancy. While 5α-reductase inhibitors appear to decrease low-grade cancer risk, they do not affect high-grade cancer risk and thus are not recommended for prevention. Supplementation with vitamins or minerals does not appear to affect the risk.Many cases are managed with active surveillance or watchful waiting. Other treatments may include a combination of surgery, radiation therapy, hormone therapy or chemotherapy. When it only occurs inside the prostate, it may be curable. In those in whom the disease has spread to the bones, pain medications, bisphosphonates and targeted therapy, among others, may be useful. Outcomes depend on a person's age and other health problems as well as how aggressive and extensive the cancer is. Most men with prostate cancer do not end up dying from the disease. The 5-year survival rate in the United States is 99%. Globally, it is the second most common type of cancer and the fifth leading cause of cancer-related death in men. In 2012, it occurred in 1.1 million men and caused 307,000 deaths. It was the most common cancer in males in 84 countries, occurring more commonly in the developed world. Rates have been increasing in the developing world. Detection increased significantly in the 1980s and 1990s in many areas due to increased PSA testing. Studies of males who died from unrelated causes have found prostate cancer in 30% to 70% of those over age 60.

Browse All Tags